Catalyst
Slingshot members are tracking this event:
Ardelyx, Inc. to Submit Detailed Results from Its First Phase 3 Trial Of Tenapanor for Hyperphosphatemia in End-Stage Renal Disease (ESRD) at The American Society Of Nephrology Kidney Week
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 11, 2017
Occurred Source:
http://ir.ardelyx.com/news-releases/news-release-details/ardelyxs-pivotal-phase-3-study-tenapanor-ibs-c-hits-primary-and
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Tenapanor, End-stage Renal Disease, Esrd, Hyperphosphatemia
